Immunotech Biopharm Ltd (Stock Code: 6978) announced the completion of its latest fundraising initiative, involving an aggregate principal of RMB270.00 million in new convertible bonds (the New Convertible Bonds) and RMB30.00 million in a note (the Note). All conditions precedent under the relevant subscription agreement have been satisfied or waived, enabling the official issuance of these instruments. According to the announcement dated 13 February 2026, the entire consideration for the subscription was applied to fully settle the principal amount of the 2023 Convertible Bonds, which were originally scheduled to mature on 20 February 2026.

The announcement also provided an updated shareholding structure, showing that the total number of issued shares stands at 617.50 million as of the announcement date. If all conversion rights under the New Convertible Bonds are exercised in full at the initial conversion price of HK$2.92, the total number of issued shares would increase to approximately 720.38 million. Following full conversion, the Investor would hold about 14.28% of the enlarged share capital, while the percentage interests of other shareholders would be adjusted accordingly.